Lehtoranta Liisa, Söderlund-Venermo Maria, Nokso-Koivisto Johanna, Toivola Hanna, Blomgren Karin, Hatakka Katja, Poussa Tuija, Korpela Riitta, Pitkäranta Anne
Institute of Biomedicine, Department of Pharmacology, University of Helsinki, PO Box 63, 00014 University of Helsinki, Finland.
Int J Pediatr Otorhinolaryngol. 2012 Feb;76(2):206-11. doi: 10.1016/j.ijporl.2011.10.025. Epub 2011 Nov 26.
Human bocavirus (HBoV) is frequently identified in children with respiratory tract infections, and its role in acute otitis media (AOM) has been suggested. The disease associations for the closely related bocaviruses HBoV2-4 remain unknown. Increasing evidence shows that probiotics may reduce the risk of AOM of viral origin. Objectives of the study was to examine the prevalence and persistence of bocaviruses in consecutive nasopharyngeal samples (NPS) of otitis-prone children, and whether an association exists between HBoV and the child's characteristics, respiratory symptoms, and AOM pathogens, and whether probiotics reduce the occurrence of HBoV.
In a double-blind, placebo-controlled, randomized, 6-month intervention study, 269 otitis-prone children (aged 9 months to 5.6 years), consumed daily either one capsule of probiotics (Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Bifidobacterium breve 99 and Propionibacterium freudenreichii JS) or placebo. After a clinical examination and NPS collected at three-time points, the presence and persistence of HBoV1-4 DNA in NPS was determined by RT-qPCR at the baseline, after 3, and 6 months.
A high load (>10,000 copies/ml) of HBoV DNA was detected in 26 (17.1%) of 152 children, and 16 (10.5%) showed a prolonged presence of HBoV for at least 3 months. None had DNA of HBoV2-4. Higher number of siblings associated with increased HBoV prevalence (p=0.029). Prevalence or persistence of HBoV was not significantly associated with other characteristics, respiratory symptoms, or AOM pathogens. Probiotic intervention significantly reduced the number of HBoV DNA-positive samples (probiotic vs. placebo: 6.4% vs. 19.0%, OR=0.25, CI 95%=0.07-0.94, p=0.039).
HBoV, but not HBoV2-4, DNA occurs often in the nasopharynx of otitis-prone children, and may persist for 3-6 months. Probiotic treatment possibly reduced the presence of HBoV.
人博卡病毒(HBoV)在呼吸道感染儿童中经常被检测到,有人提出其在急性中耳炎(AOM)中发挥作用。与HBoV密切相关的博卡病毒HBoV2 - 4与疾病的关联尚不清楚。越来越多的证据表明,益生菌可能会降低病毒源性AOM的风险。本研究的目的是检测易患中耳炎儿童连续鼻咽样本(NPS)中博卡病毒的流行率和持续存在情况,以及HBoV与儿童特征、呼吸道症状和AOM病原体之间是否存在关联,以及益生菌是否能减少HBoV的发生。
在一项双盲、安慰剂对照、随机的6个月干预研究中,269名易患中耳炎儿童(年龄9个月至5.6岁)每天服用一粒益生菌胶囊(鼠李糖乳杆菌GG、鼠李糖乳杆菌Lc705、短双歧杆菌99和费氏丙酸杆菌JS)或安慰剂。在三个时间点进行临床检查并采集NPS后,通过逆转录定量聚合酶链反应(RT-qPCR)在基线、3个月和6个月时检测NPS中HBoV1 - 4 DNA的存在情况和持续存在情况。
在152名儿童中的26名(17.1%)检测到高载量(>10,000拷贝/ml)的HBoV DNA,16名(10.5%)显示HBoV持续存在至少3个月。未检测到HBoV2 - 4的DNA。兄弟姐妹数量较多与HBoV流行率增加相关(p = 0.029)。HBoV的流行率或持续存在情况与其他特征、呼吸道症状或AOM病原体无显著关联。益生菌干预显著减少了HBoV DNA阳性样本的数量(益生菌组与安慰剂组:6.4%对19.0%,比值比[OR]=0.25,95%置信区间[CI]=0.07 - 0.94,p = 0.039)。
HBoV(而非HBoV2 - 4)DNA在易患中耳炎儿童的鼻咽部中经常出现,且可能持续存在3至6个月。益生菌治疗可能减少了HBoV的存在。